A Phase 3 interventional study of Letermovir in Cytomegalovirus Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 21 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-25.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing letermovir in Cytomegalovirus Infections — 7 open to participants now, 8 under way, 3 of them phase 3. letermovir · Cytomegalovirus Infections.
Among the 17 studies testing letermovir in Cytomegalovirus Infections, this one is the 4th largest by enrollment, is one of 4 that started in 2023, is one of 6 in phase 3, and was the 8th registered.
370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.
Browse Cytomegalovirus Infections studies →7 of the 17 studies testing letermovir in Cytomegalovirus Infections are open now, in 4 countries. Recruiting first, the newest first:
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
Elisabeth Kincaide · Sites in United States
Ages 18+
Hospital do Rim e Hipertensão
Ages 18+
By country, each count listing its studies:
letermovir: first FDA approval 2017 (PREVYMIS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 4 started in 2023.
This study's enrollment of 120 is above the median of 64 across 240 interventional studies indexed under Cytomegalovirus Infections.
Median enrollment 80 across the 17 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 8 studies filed under Cytomegalovirus Infections — fewer than ten, so there is no comparison to draw.
4 of the studies testing letermovir in Cytomegalovirus Infections that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06407232Phase 3University of Wisconsin, MadisonLetermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients | 2027-08 |
| NCT06334497Phase 3Assistance Publique - Hôpitaux de ParisLetermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections | 2027-09 |
| NCT06066957University of PennsylvaniaOpen Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients | 2026-12-15 |
| NCT06057194Maimónides Biomedical Research Institute of CórdobaEfficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir. | 2027-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 17 studies testing letermovir in Cytomegalovirus Infections, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of a once-a-day oral or intravenous (IV) dose of Letermovir (MK-8228) in Chinese adult hematopoietic stem cell transplant (HSCT) recipients for the prevention of clinically significant cytomegalovirus (CMV) infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The key inclusion and exclusion criteria include but are not limited to the following:
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chinese HSCT recipients will receive 240 mg of Letermovir \[for participants on Cyclosporin A (CsA)\] or 480 mg of Letermovir (for participants not on CsA) either orally or IV once daily through week 14 (\~100 days) post-transplant.
Drug: Letermovir
Daily 240 mg or 480 mg oral tablets or IV dose
Also known as: MK-8228
Percentage of Participants With Clinically Significant Cytomegalovirus (CMV) Infection up to Week 24 Post-Transplant
Clinically significant CMV infection was defined as either one of the following: 1) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant or 2) onset of CMV end-organ disease. The percentage of participants with clinically significant CMV infection up to week 24 post-transplant is reported.
Time frame: Up to Week 24 post-transplant (approximately 6 months)
Percentage of Participants Who Experienced an Adverse Event (AE)
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE is reported.
Time frame: Up to 16 weeks
Percentage of Participants Who Discontinue Study Treatment Due to an Adverse Event
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study treatment due to an AE is reported.
Time frame: Up to 14 weeks
Percentage of Participants With Clinically Significant CMV Infection up to Week 14 Post-Transplant
Clinically significant CMV infection was defined as either one of the following: 1) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant or 2) onset of CMV end-organ disease. The percentage of participants with clinically significant CMV infection up to 14 weeks post-transplant is reported.
Time frame: Up to 14 weeks post-transplant (99 days)
Percentage of Participants With Preemptive Therapy for CMV Viremia up to Week 14 Post-Transplant
Initiation of anti-CMV preemptive therapy was based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with initiation of anti-CMV preemptive anti-CMV therapy up to 14 weeks post-transplant is reported.
Time frame: Up to 14 weeks post-transplant (99 days)
Percentage of Participants With Preemptive Therapy for CMV Viremia up to Week 24 Post-Transplant
Initiation of anti-CMV preemptive therapy was based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with initiation of anti-CMV preemptive anti-CMV therapy up to 24 weeks post-transplant is reported.
Time frame: Up to 24 weeks post-transplant (approximately 6 months)
Percentage of Participants With CMV End-organ Disease up to Week 14 Post-Transplant
CMV end-organ disease met per-protocol diagnostic criteria for CMV-pneumonia, gastrointestinal disease, hepatitis, central nervous system disease, retinitis, nephritis, cystitis, myocarditis, pancreatitis, or other disease categories. Only Clinical Adjudication Committee-confirmed CMV end-organ disease will be included in this analysis. The percentage of participants with CMV end-organ disease up to 14 weeks post-transplant is reported.
Time frame: Up to 14 weeks post-transplant (99 days)
Percentage of Participants With CMV End-organ Disease up to Week 24 Post-Transplant
CMV end-organ disease met per-protocol diagnostic criteria for CMV-pneumonia, gastrointestinal disease, hepatitis, central nervous system disease, retinitis, nephritis, cystitis, myocarditis, pancreatitis, or other disease categories. Only Clinical Adjudication Committee-confirmed CMV end-organ disease will be included in this analysis. The percentage of participants with CMV end-organ disease up to 24 weeks post-transplant is reported.
Time frame: Up to 24 weeks post-transplant (approximately 6 months)
Percentage of Participants With All-Cause Mortality up to Week 14 Post-Transplant
The percentage of participants who died due to any cause up to 14 weeks post-transplant is reported.
Time frame: Up to 14 weeks post-transplant (99 days)
Percentage of Participants With All-cause Mortality up to Week 24 Post-Transplant
The percentage of participants who died due to any cause up to 24 weeks post-transplant is reported.
Time frame: Up to 24 weeks post-transplant (approximately 6 months)
| Milestone | Letermovir |
|---|---|
| Started | 120 |
| Completed | 107 |
| Not completed | 13 |
| Withdrew: Death | 6 |
| Withdrew: Withdrawal by parent/guardian | 1 |
| Withdrew: Withdrawal by subject | 6 |
Clinically significant CMV infection was defined as either one of the following: 1) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant or 2) onset of CMV end-organ disease. The percentage of participants with clinically significant CMV infection up to week 24 post-transplant is reported.
| Percentage of Participants | Letermovir |
|---|---|
| Percentage of Participants With Clinically Significant Cytomegalovirus (CMV) Infection up to Week 24 Post-Transplant | 32 (23.5 to 42.9) |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE is reported.
| Percentage of Participants | Letermovir |
|---|---|
| Percentage of Participants Who Experienced an Adverse Event (AE) | 99.2 (95.4 to 100.0) |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study treatment due to an AE is reported.
| Percentage of Participants | Letermovir |
|---|---|
| Percentage of Participants Who Discontinue Study Treatment Due to an Adverse Event | 0 (NA to NA) |
Clinically significant CMV infection was defined as either one of the following: 1) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant or 2) onset of CMV end-organ disease. The percentage of participants with clinically significant CMV infection up to 14 weeks post-transplant is reported.
| Percentage of Participants | Letermovir |
|---|---|
| Percentage of Participants With Clinically Significant CMV Infection up to Week 14 Post-Transplant | 7.1 (2.9 to 14.2) |
Initiation of anti-CMV preemptive therapy was based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with initiation of anti-CMV preemptive anti-CMV therapy up to 14 weeks post-transplant is reported.
| Percentage of Participants | Letermovir |
|---|---|
| Percentage of Participants With Preemptive Therapy for CMV Viremia up to Week 14 Post-Transplant | 7.1 (2.9 to 14.2) |
Initiation of anti-CMV preemptive therapy was based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with initiation of anti-CMV preemptive anti-CMV therapy up to 24 weeks post-transplant is reported.
| Percentage of Participants | Letermovir |
|---|---|
| Percentage of Participants With Preemptive Therapy for CMV Viremia up to Week 24 Post-Transplant | 32.7 (23.5 to 42.9) |
CMV end-organ disease met per-protocol diagnostic criteria for CMV-pneumonia, gastrointestinal disease, hepatitis, central nervous system disease, retinitis, nephritis, cystitis, myocarditis, pancreatitis, or other disease categories. Only Clinical Adjudication Committee-confirmed CMV end-organ disease will be included in this analysis. The percentage of participants with CMV end-organ disease up to 14 weeks post-transplant is reported.
| Percentage of Participants | Letermovir |
|---|---|
| Percentage of Participants With CMV End-organ Disease up to Week 14 Post-Transplant | 6.1 (2.3 to 12.9) |
CMV end-organ disease met per-protocol diagnostic criteria for CMV-pneumonia, gastrointestinal disease, hepatitis, central nervous system disease, retinitis, nephritis, cystitis, myocarditis, pancreatitis, or other disease categories. Only Clinical Adjudication Committee-confirmed CMV end-organ disease will be included in this analysis. The percentage of participants with CMV end-organ disease up to 24 weeks post-transplant is reported.
| Percentage of Participants | Letermovir |
|---|---|
| Percentage of Participants With CMV End-organ Disease up to Week 24 Post-Transplant | 11.2 (5.7 to 19.2) |
The percentage of participants who died due to any cause up to 14 weeks post-transplant is reported.
| Percentage of Participants | Letermovir |
|---|---|
| Percentage of Participants With All-Cause Mortality up to Week 14 Post-Transplant | 5.1 (1.7 to 11.5) |
The percentage of participants who died due to any cause up to 24 weeks post-transplant is reported.
| Percentage of Participants | Letermovir |
|---|---|
| Percentage of Participants With All-cause Mortality up to Week 24 Post-Transplant | 6.1 (2.3 to 12.9) |
Collected over Up to 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Letermovir | 8/120 (6.7%) | 70/120 (58.3%) | 118/120 (98.3%) |
| Event | Letermovir |
|---|---|
| PneumoniaInfections and infestations | 17/120 |
| Acute graft versus host diseaseImmune system disorders | 14/120 |
| Cystitis haemorrhagicRenal and urinary disorders | 12/120 |
| Epstein-Barr virus infectionInfections and infestations | 8/120 |
| Cytomegalovirus infectionInfections and infestations | 7/120 |
| Epstein-Barr viraemiaInfections and infestations | 6/120 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/120 |
| Acute graft versus host disease in intestineImmune system disorders | 4/120 |
| Cytomegalovirus viraemiaInfections and infestations | 4/120 |
| AnaemiaBlood and lymphatic system disorders | 3/120 |
| Event | Letermovir |
|---|---|
| HypokalaemiaMetabolism and nutrition disorders | 39/120 |
| VomitingGastrointestinal disorders | 37/120 |
| PyrexiaGeneral disorders | 32/120 |
| NauseaGastrointestinal disorders | 27/120 |
| White blood cell count decreasedInvestigations | 27/120 |
| RashSkin and subcutaneous tissue disorders | 26/120 |
| DiarrhoeaGastrointestinal disorders | 25/120 |
| Epstein-Barr virus infectionInfections and infestations | 20/120 |
| Platelet count decreasedInvestigations | 20/120 |
| HyponatraemiaMetabolism and nutrition disorders | 20/120 |
| Age, Continuous(Years) | Letermovir |
|---|---|
| Mean | 37.8 ± 12.1 |
| Sex: Female, Male(Participants) | Letermovir |
|---|---|
| Female | 45 |
| Male | 75 |
| Ethnicity (NIH/OMB)(Participants) | Letermovir |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 120 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Letermovir |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 120 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Mar 2023 to primary completion in Apr 2024, 12 months.
Results were first posted in Mar 2025, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Letermovir